Skip to main content
Premium Trial:

Request an Annual Quote

Sanofi to Test Vaccine Candidate

Sanofi is launching a clinical trial of a candidate mRNA-based vaccine for SARS-CoV-2, the Financial Times reports.

It notes that Sanofi originally focused in conjunction with GlaxoSmithKline on a SARS-CoV-2 vaccine based on recombinant protein. But the two companies reported in December that their candidate vaccine raised an insufficient immune response in early-stage clinical trials, delaying their timeline.

But as Barron's reports, Sanofi has also been working with US-based Translate Bio on an mRNA-based vaccine, like those from Pfizer-BioNTech and Moderna. Sanofi and Translate are now starting a Phase 1/2 trial into which they plan to enroll 415 participants to assess the candidate vaccine's safety, dosing, and possible side effects, according to Forbes. It adds that the companies expect interim results by the third quarter of the year.

Sanofi and Translate are also beginning early-stage studies of other candidate vaccines aimed at SARS-CoV-2 variants, FT adds.

It notes that France has viewed the inability of Sanofi or the Pasteur Institute — which ended its vaccine effort in January following disappointing results — to bring a vaccine to market as a national embarrassment.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.